摘要
目的 观察麝香保心丸联合曲美他嗪对急性心肌梗死(AMI)治疗效果。方法 将我院198例AMI患者随机分为治疗组与对照组各99例。两组均参考指南进行基础治疗,对照组在基础治疗上加服曲美他嗪,治疗组在对照组治疗基础上加服麝香保心丸,治疗3个月后观察疗效,并比较两组治疗前后心功能指标[左室舒张末期容积指数(LVEF)、心排血量(CO)、心脏指数(CI)、每搏排心量(SV)]、心肌重构指标[左室重构指数(LVRI)、左室质量指数(LVMI)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)]、炎症因子指标[肿瘤坏死因子-α(TNF-α)、白介素6(IL-6)、白介素-23(IL-23)]与氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、晚期氧化蛋白产物(AOPP)],并观察治疗期间不良反应情况。结果 治疗后两组LVEF、CO、CI、SV指标显著升高(P<0.05),LVRI、LVMI、LVESD、LVEDD显著降低(P<0.05),且两组上述指标比较差异均有统计学意义(P<0.05);两组TNF-α、IL-6、IL-23指标显著降低(P<0.05),SOD指标显著上升(P<0.05),MDA、AOPP指标显著降低(P<0.05),且两组上述指标差异均有统计学意义(P<0.05);两组治疗期间均未见明显不良反应。结论 麝香保心丸联合曲美他嗪治疗急性心肌梗死患者的临床疗效良好,可改善心功能及心肌重构减少SOD的消耗量抑制氧化应激减轻炎症反应,值得推介。
Objective To observe the clinical effect of Shexiang Baoxin Pills combined with trimetazidine on patients with acute myocardial infarction(AMI).Methods A total of 198 patients with AMI were randomly divided into treatment group and control group,99 cases each.Both groups were given basic treatment according to the guidelines,and control group was given trimetazidine on this basis while treatment group was additionally treated with Shexiang Baoxin Pills on the basis of control group.The efficacy was observed after 3 months of treatment.Cardiac function indicators [left ventricular end diastolic volume index(LVEF), cardiac output(CO), cardiac index(CI),stroke volume(SV)],myocardial remodeling indicators [left ventricular remodeling index(LVRI),left ventricular mass index(LVMI),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD)], inflammatory factors [tumor necrosis factor-α(TNF-α),interleukin(IL)-6,IL-23] and oxidative stress indicators [superoxide dismutase(SOD), malondialdehyde(MDA), advanced oxidation protein products(AOPP)] were compared between the two groups before and after treatment.The adverse reactions during treatment were observed.Results After treatment,the LVEF,CO,CI and SV of both groups were enhanced significantly(P<0.05) while the LVRI,LVMI,LVESD and LVEDD were significantly reduced(P<0.05),and there were statistical differences in the above indicators in treatment group compared with those in control group(P<0.05),the levels of TNF-α,IL-6 and IL-23 were significantly lowered in both groups(P<0.05),and the level of SOD was increased significantly(P<0.05) while the MDA and AOPP were decreased significantly(P<0.05),and the differences in the above indicators were statistically significant between treatment group and control group(P<0.05);there were no obvious adverse reactions during treatment in the two groups.Conclusion Shexiang Baoxin Pills combined with trimetazidine has a good clinical efficacy in treatment of acute myocardial infarction.In addition,
作者
张蓓
卢晓
ZHANG Bei;LU Xiao(Wuhan Hospital of Traditional Chinese and Western Medicine/Wuhan No.1 Hospital,Wuhan 430030)
出处
《湖北中医药大学学报》
2022年第3期28-31,共4页
Journal of Hubei University of Chinese Medicine
基金
武汉市卫生健康委科技计划项目(项目编号:WZ14A06)。
关键词
急性心肌梗死
麝香保心丸
曲美他嗪
Acute myocardial infarction
Shexiang Baoxin Pills
Trimetazidine
